Search tips
Search criteria 


Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
Infect Immun. 1993 May; 61(5): 1990–1995.
PMCID: PMC280793

Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis.


Women with recurrent vulvovaginal candidiasis often demonstrate a down-regulation of cell-mediated immunity (CMI) to Candida albicans detected by a lack of cutaneous delayed-type hypersensitivity (DTH) to Candida antigens. However, the role of systemic CMI as a host defense mechanism against recurrent vulvovaginal candidiasis is not well understood, in part because of the lack of a well-defined murine model of vaginal candidiasis. The present study was undertaken to determine: (i) whether soluble Candida culture filtrate antigens (CaCF) could be used to induce and detect Candida-specific CMI in mice and (ii) whether these antigens would be useful in detecting systemic CMI in mice given an experimental Candida vaginal infection. To this end, mice were immunized subcutaneously with CaCF in complete Freund's adjuvant, and within 7 days they developed Candida-specific DTH reactivity detected by footpad swelling (increase in footpad thickness, 0.36 mm) 24 h after footpad challenge with CaCF. Adoptive transfer studies showed that the DTH responsiveness was elicited by CD4+ DTH T cells. In mice given a vaginal inoculum of C. albicans blastoconidia (5 x 10(5)), footpad challenge with CaCF resulted in positive DTH responses (0.24 mm) as early as 1 week, responses similar to immunization in 2 to 3 weeks (0.33 mm), and sustained low levels of DTH reactivity (0.15 mm) through 10 weeks of vaginal infection. Vaginal lavage cultures revealed that peak vaginal Candida burden occurred 1 week post-vaginal inoculation (10(5) CFU) and declined 16-fold by week 10. These results provide evidence that Candida-specific systemic CMI is generated and can be detected longitudinally in mice with Candida vaginitis by a multiantigen preparation of Candida organisms which both initiates and detects Candida-specific CMI.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aronson IK, Rieger CH, Soltani K, Tkalcevic V, Chan WC, Lorincz AL, Matz G. Late onset chronic mucocutaneous candidiasis with lymphoma and specific serum inhibitory factor. Cancer. 1979 Jan;43(1):101–108. [PubMed]
  • Balish E, Filutowicz H, Oberley TD. Correlates of cell-mediated immunity in Candida albicans-colonized gnotobiotic mice. Infect Immun. 1990 Jan;58(1):107–113. [PMC free article] [PubMed]
  • Barnaba V, Zaccari C, Levrero M, Balsano F. Suppressor T cells role in the unresponsiveness to Candida albicans in chronic mucocutaneous candidiasis. Boll Ist Sieroter Milan. 1985;64(2):126–130. [PubMed]
  • Buckley RH, Lucas ZJ, Hattler BG, Jr, Zmijewski CM, Amos DB. Defective cellular immunity associated with chronic mucocutaneous moniliasis and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow. Clin Exp Immunol. 1968 Feb;3(2):153–169. [PubMed]
  • Canales L, Middlemas RO, 3rd, Louro JM, South MA. Immunological observations in chronic mucocutaneous candidiasis. Lancet. 1969 Sep 13;2(7620):567–571. [PubMed]
  • Cantorna MT, Balish E. Mucosal and systemic candidiasis in congenitally immunodeficient mice. Infect Immun. 1990 Apr;58(4):1093–1100. [PMC free article] [PubMed]
  • Cantorna MT, Balish E. Role of CD4+ lymphocytes in resistance to mucosal candidiasis. Infect Immun. 1991 Jul;59(7):2447–2455. [PMC free article] [PubMed]
  • Carrow EW, Domer JE. Immunoregulation in experimental murine candidiasis: specific suppression induced by Candida albicans cell wall glycoprotein. Infect Immun. 1985 Jul;49(1):172–181. [PMC free article] [PubMed]
  • Cauley LK, Murphy JW. Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect Immun. 1979 Mar;23(3):644–651. [PMC free article] [PubMed]
  • Chilgren RA, Quie PG, Meuwissen HJ, Hong R. Chronic mucocutaneous candidiasis, deficiency of delayed hypersensitivity, and selective local antibody defect. Lancet. 1967 Sep 30;2(7518):688–693. [PubMed]
  • Domer JE, Garner RE, Befidi-Mengue RN. Mannan as an antigen in cell-mediated immunity (CMI) assays and as a modulator of mannan-specific CMI. Infect Immun. 1989 Mar;57(3):693–700. [PMC free article] [PubMed]
  • Durandy A, Fischer A, Le Deist F, Drouhet E, Griscelli C. Mannan-specific and mannan-induced T-cell suppressive activity in patients with chronic mucocutaneous candidiasis. J Clin Immunol. 1987 Sep;7(5):400–409. [PubMed]
  • Fischer A, Ballet JJ, Griscelli C. Specific inhibition of in vitro Candida-induced lymphocyte proliferation by polysaccharidic antigens present in the serum of patients with chronic mucocutaneous candidiasis. J Clin Invest. 1978 Nov;62(5):1005–1013. [PMC free article] [PubMed]
  • Fleury FJ. Adult vaginitis. Clin Obstet Gynecol. 1981 Jun;24(2):407–438. [PubMed]
  • Fong IW, McCleary P, Read S. Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis. Am J Obstet Gynecol. 1992 Mar;166(3):887–890. [PubMed]
  • Garner RE, Childress AM, Human LG, Domer JE. Characterization of Candida albicans mannan-induced, mannan-specific delayed hypersensitivity suppressor cells. Infect Immun. 1990 Aug;58(8):2613–2620. [PMC free article] [PubMed]
  • Gatenby P, Basten A, Adams E. Thymoma and late onset mucocutaneous candidiasis associated with a plasma inhibitor of cell-mediated immune function. J Clin Lab Immunol. 1980 May;3(3):209–216. [PubMed]
  • Hobbs JR, Brigden D, Davidson F, Kahan M, Oates JK. Immunological aspects of candidal vaginitis. Proc R Soc Med. 1977;70 (Suppl 4):11–14. [PubMed]
  • Hurley R. Candidal vaginitis. Proc R Soc Med. 1977;70 (Suppl 4):1–2. [PubMed]
  • Hurley R. Recurrent Candida infection. Clin Obstet Gynaecol. 1981 Apr;8(1):209–214. [PubMed]
  • Hurley R, De Louvois J. Candida vaginitis. Postgrad Med J. 1979 Sep;55(647):645–647. [PMC free article] [PubMed]
  • Jimenez-Finkel BE, Murphy JW. Characterization of efferent T suppressor cells induced by Paracoccidioides brasiliensis-specific afferent T suppressor cells. Infect Immun. 1988 Apr;56(4):744–750. [PMC free article] [PubMed]
  • Kirkpatrick CH, Chandler JW, Schimke RN. Chronic mucocutaneous moniliasis with impaired delayed hypersensitivity. Clin Exp Immunol. 1970 Mar;6(3):375–385. [PubMed]
  • Marquis G, Montplaisir S, Pelletier M, Mousseau S, Auger P. Strain-dependent differences in susceptibility of mice to experimental candidosis. J Infect Dis. 1986 Nov;154(5):906–909. [PubMed]
  • McCourtie J, Douglas LJ. Relationship between cell surface composition of Candida albicans and adherence to acrylic after growth on different carbon sources. Infect Immun. 1981 Jun;32(3):1234–1241. [PMC free article] [PubMed]
  • Morton RS, Rashid S. Candidal vaginitis: natural history, predisposing factors and prevention. Proc R Soc Med. 1977;70 (Suppl 4):3–6. [PubMed]
  • Murphy JW, Moorhead JW. Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J Immunol. 1982 Jan;128(1):276–283. [PubMed]
  • Narayanan R, Joyce WA, Greenfield RA. Gastrointestinal candidiasis in a murine model of severe combined immunodeficiency syndrome. Infect Immun. 1991 Jun;59(6):2116–2119. [PMC free article] [PubMed]
  • Paterson PY, Semo R, Blumenschein G, Swelstad J. Mucocutaneous candidiasis, anergy and a plasma inhibitor of cellular immunity: reversal after amphotericin B therapy. Clin Exp Immunol. 1971 Nov;9(5):595–602. [PubMed]
  • Piccolella E, Lombardi G, Morelli R. Human lymphocyte-activating properties of a purified polysaccharide from Candida albicans: B and T cell cooperation in the mitogenic response. J Immunol. 1980 Nov;125(5):2082–2088. [PubMed]
  • Piccolella E, Lombardi G, Morelli R. Generation of suppressor cells in the response of human lymphocytes to a polysaccharide from Candida albicans. J Immunol. 1981 Jun;126(6):2151–2155. [PubMed]
  • Rhoads JL, Wright DC, Redfield RR, Burke DS. Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA. 1987 Jun 12;257(22):3105–3107. [PubMed]
  • Ryley JF, McGregor S. Quantification of vaginal Candida albicans infections in rodents. J Med Vet Mycol. 1986 Dec;24(6):455–460. [PubMed]
  • Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann N Y Acad Sci. 1988;544:547–557. [PubMed]
  • Sobel JD, Muller G, McCormick JF. Experimental chronic vaginal candidosis in rats. Sabouraudia. 1985 Jun;23(3):199–206. [PubMed]
  • Syverson RE, Buckley H, Gibian J, Ryan GM., Jr Cellular and humoral immune status in women with chronic Candida vaginitis. Am J Obstet Gynecol. 1979 Jul 15;134(6):624–627. [PubMed]
  • Twomey JJ, Waddell CC, Krantz S, O'reilly R, L'esperance P, Good RA. Chronic mucocutaneous candidiasis with macrophage dysfunction, a plasma inhibitor, and co-existent aplastic anemia. J Lab Clin Med. 1975 Jun;85(6):968–977. [PubMed]
  • Witkin SS. Inhibition of Candida-induced lymphocyte proliferation by antibody to Candida albicans. Obstet Gynecol. 1986 Nov;68(5):696–699. [PubMed]
  • Witkin SS, Hirsch J, Ledger WJ. A macrophage defect in women with recurrent Candida vaginitis and its reversal in vitro by prostaglandin inhibitors. Am J Obstet Gynecol. 1986 Oct;155(4):790–795. [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)